In the CorEvitas registry, a significant portion of people with treatment-resistant active PsA and using the Janssen Pharmaceuticals drug in the real-world settings, had meaningful improvements in pain, physical function, and fatigue through six months
Tremfya has improved patient-reported results in people living with treatment-resistant active psoriatic arthritis. (Credit: Towfiqu barbhuiya on Unsplash)
Janssen Pharmaceuticals, a part of Johnson & Johnson, said that Tremfya (guselkumab) has shown clinically meaningful improvements in patient-reported outcomes for adults living with active psoriatic arthritis (PsA), as per new data from the CorEvitas PsA and Spondyloarthritis Registry.
Tremfya is an approved fully human monoclonal selective interleukin (IL)-23p19-subunit inhibitor therapy for active PsA. It is designed to bind to the p19 subunit of IL-23 and prevents its interaction with the IL-23 receptor.
In the registry, a significant portion of people living with treatment-resistant active PsA and using the Janssen Pharmaceuticals drug in the real-world settings, reported meaningful improvements in pain, physical function, and fatigue through six months.
Furthermore, in the DISCOVER-1, DISCOVER-2, and COSMOS clinical trials, Tremfya demonstrated higher rates of clinically meaningful improvements.
The drug showed enhancements in a composite assessment of patient-reported pain, fatigue, physical function, skin problems, and PsA-related depression. This was in comparison to placebo in the first evaluation of the PsA 5-Thermometer Scale Domains (PsA-5T-Ds).
According to the CorEvitas data, patients who are resistant to treatment reported significant improvements in their level of pain, exhaustion, and physical function.
The analysis of the findings found that considerable proportions of on-label Tremfya persisters confirmed clinically meaningful improvements from baseline.
Additionally, the analysis of the DISCOVER-1, DISCOVER-2, and COSMOS trials across key PsA patient-reported outcomes supported the efficacy of IL-23p19-subunit inhibitor for patients who were bio-naïve or tumour necrosis factor inhibitors (TNFis)-experienced.
Janssen Research & Development immunology disease area leader and rheumatology vice president Terence Rooney said: “These new TREMFYA results demonstrate our commitment to addressing symptoms that impact people living with active psoriatic arthritis, including depression, pain, fatigue, physical function and skin problems.
“It is critical that we evaluate patient-reported outcomes to truly understand the lived experiences of patients and better develop and provide treatments in psoriatic disease.”
In 2020, Tremfya was approved by the US Food and Drug Administration and the European Commission (EC) to treat active psoriatic arthritis.